2023
March 14th
Affiche Diner double cursus amps

Double-Curriculum Dinners of AMPS

The double-curricular dinners are one of the flagship events of the Association Médecine Pharmacie Sciences (AMPS). During these events, a guest presents his or her work and career to the public during a lecture. Then, a discussion between students and the speaker follows around a drink and a buffet.

Program: Lecture (in French) by Prof. Françoise Galateau-Sallé from 7:30 pm to 10 pm on Friday, March 31 at the Institut Curie (Chez Marie). 1h presentation broadcasted by videoconference, then 1h30 of discussions around an aperitif-dinner.

Participation in the dinner is free and is based on an online registration form.

For the 5th edition of the double-curricular dinners, Professor Françoise Galateau-Sallé, anatomopathologist and researcher - specialized in the study of mesothelioma - will tell us about her career and her work during this event.

Since 1980, Professor Galateau-Sallé has participated in the creation of Mesopath (malignant mesothelioma network) at the Biopathology Cancer Center Léon Bérard in Lyon, where she also works as an anatomo-pathologist. Mesopath is a network of experts spread all over France, at the origin of a standardized diagnostic validation procedure unique in the world allowing to refine considerably the diagnosis by standardizing the anatomopathological practices and the sampling procedures in the framework of pleural mesothelioma. Thus, she is developing a research activity in order to understand the mechanisms of cancerous transformation of the pleura and to identify biomarkers capable of recognizing precancerous states and of identifying unusual forms of mesothelioma among the included tumors. Professor Galateau-Sallé is also an editor at the Archives of Pathology & Laboratory Medicine, an editorial consultant to the European Society of Pathology and an expert at the National Cancer Institute.  

Her research interests include mesothelial proliferation (benign and malignant), predictive biomarkers for mesothelioma, biobanking and artificial intelligence in pathology.